CH5424802_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:CH5424802 is a potent, selective, and orally available ALK inhibitor with IC 50 of 1.9 nM, the dissociation constant (K D ) value for ALK in an ATP–competitive manner is 2.4 nM using a competition–binding assay.IC50 & Target: IC50: 1.9 nM(ALK), 1 nM (ALK F1174L ), 3.5 nM (ALK R1275Q )[1]Kd: 2.4 nM (ALK)[1]In Vitro: CH5424802 prevents autophosphorylation of ALK in NCI–H2228 NSCLC cells expressing EML4–ALK, and CH5424802 also results in substantial suppression of phosphorylation of STAT3 and AKT, but not of ERK1/2[1]. CH5424802 shows high kinase selectivity and strong anti–proliferative activity against KARPAS–299 with an IC 50 value of 3 nM [2].In Vivo: In the NCI–H2228 model, once–daily oral administration of CH5424802 results in dose–dependent tumor growthinhibition (ED 50=0.46 mg/kg) and tumor regression. Treatment of 20 mg/kg CH5424802 shows rapid tumor regression (168% tumor growth inhibition; p<0.001), the tumor volume in any mouse is <30 mm 3 after 11 days of treatment (at day 28), a potent antitumor effect is maintained, and tumor re–growth dpes not occur throughout the 4–week drug–free period [1]. Oral administration of CH5424802 at 20 mg/kg displays significant tumor regression without body weight loss in an established ALK fusion gene–positiveNSCLC xenograft model in mice [2]. CH5424802 (Alectinib) at 60 mg/kg causes tumor regression against EML4–ALK–positive NCI–H2228 xenograft model and decreases the levels of phosphorylated ALK in this model. In addition, in mice at dose levels up to 60 mg/kg of CH5424802, there is no body weight loss, no significant change in peripheral blood cell count, no elevations of aspartate aminotransferase or alanine aminotransferase, and no substantial change in electrolytes. Oral administration ofCH5424802 at 60 mg/kg for 4 days results in significant tumor regression seen in the luminescence signal [3].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]The inhibitory ability against each kinase except for MEK1 and Raf–1 is evaluated by examining their ability to phosphorylate various substrate peptides in the presence of CH5424802 using time–resolved fluorescence resonance energy transfer (TR–FRET) assay or fluorescence polarization (FP) assay. The inhibitory activity against MEK1 is evaluated by quantitative analysis of the phosphorylation of a substrate peptide by a recombinant ERK2 protein in the presence of CH5424802. The inhibitory activity against Raf–1 is evaluated by examining the ability of the kinases to phosphorylate MEK1 in the presence of CH5424802[1].Cell Assay: CH5424802 is dissolved in DMSO and stored, and then diluted with appropriate media before use [1].[1]Cells are culturedin 96–well plates overnight and incubated with various concentrations of CH5424802 for the indicated time. For spheroid cell growth inhibition assay, cells are seeded on spheroid plates, incubated overnight, and then treated with CH5424802 for theindicated times. The viable cells are measured by the CellTiter–Glo Luminescent Cell Viability Assay. Caspase–3/7 assay is evaluated using the Caspase–Glo 3/7 Assay Kit [1].Animal Administration: CH5424802 is dissolved in 0.02 N HCl, 10% DMSO, 10% Cremophor EL, 15% PEG400, and 15%HPCD (2–hydroxypropyl–β–cyclodextrin) (Mice)[1].[1][3]Mice [1]Product Name:CH5424802Cat. No.:HY-13011CAS No.:1256580-46-7Molecular Formula:C 30H 34N 4O 2Molecular Weight:482.62Target:ALK Pathway:Protein Tyrosine Kinase/RTK Solubility:DMSO: 6.2 mg/mL (Need warming)Cell lines are grown as s.c. tumors in SCID or nude mice. Therapeutic experiments are started (day 0) when the tumor reaches ~250 or ~350 mm3. Mice are randomized to treatment groups to receive vehicle or CH5424802 (oral, qd) for the indicated duration.Final concentration of vehicle is 0.02 N HCl, 10% DMSO, 10% Cremophor EL, 15% PEG400, and 15% HPCD(2–hydroxypropyl–β–cyclodextrin). The length (L) and width (W) of the tumor mass are measured, and the tumor volume (TV) is calculated as: TV=(L×W2)/2. Tumor growth inhibition is calculated using the following formula: tumor growth inhibition=[1-(T-T0)/(C-C0)]×100. The ED50 is calculated from the values of tumor growth inhibition on the final experimental day.Rat[3]Plasma and brain (cerebrum and cerebellum) samples are prepared at various time points between 4 and 168 h after a single oral administration of 14C–labeled CH5424802 (Alectinib) at 1 mg/kg to a rat. The radioactivity concentrations in plasma are determined by a liquid scintillation counter, and the radioactivity concentrations in brain are quantified using quantitative whole–body autography.References:[1]. Sakamoto H, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011, 19(5), 679–690.[2]. Kinoshita K, et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem. 2012, 20(3), 1271–1280.[3]. Kodama T, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014 Nov; 74(5):1023–8.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。